Noopept (omberacetam; GVS-111)

omberacetam, a small-molecule cognitive drug sold as a registered 10 mg oral tablet in Russia. the cited human signal comes from one small patient comparison, not a healthy-user trial.

tier B · focus · 53 patients enrolled in the main active-comparator study

verdict

Noopept has a current Russian drug registration and a limited patient signal. It does not have placebo-controlled evidence of cognitive enhancement in healthy people, and sampled US supplements did not reliably define the exposure.

why B-tier

B-tier reflects a current foreign registration, one small positive active-comparator patient study, and direct but sparsely reported human pharmacokinetics. It stays below A because the clinical study had no placebo or healthy-user group, long-term healthy-user safety is absent, and US supplement identity is a separate unresolved problem.

the core tension

A current Russian tablet, a small patient comparison, and sampled US supplements are three different records. None establishes placebo-controlled cognitive enhancement in healthy people.

what it is

Noopept is omberacetam, also called GVS-111: N-phenylacetyl-L-prolylglycine ethyl ester, a synthetic small molecule built from a proline-glycine scaffold. It is not an amino-acid-chain peptide. FDA's substance record lists formula C17H22N2O4, molecular weight 318.37 g/mol, and CAS 157115-85-0. Russia currently registers Noopept 10 mg tablets under certificate ЛП-N(004920)-(РГ-RU), dated 2024-03-20.

what it does

People seek Noopept for memory and focus, but the cited record does not establish a human receptor or target mechanism. The direct human measurements are a short pharmacokinetic report and outcomes from a 56-day patient comparison. The rat papers answer separate model questions, and a 2019 study found no group difference in spatial learning or hippocampal NGF or BDNF. Those animal results cannot explain or prove healthy-user cognitive enhancement.

origin

Noopept was developed in Russia as GVS-111. The current Russian product is an oral 10 mg tablet registered for adult cognitive disorders described in its product characteristics. The internationally indexed human record in this file is much narrower: one small Noopept-versus-piracetam comparison and one sparsely reported pharmacokinetic abstract.

does it work

The 2009 paper enrolled 53 patients with vascular or post-traumatic cognitive impairment: 31 were assigned Noopept, 22 piracetam, and 41 completed 56 days. The authors reported clinical and cognitive improvement. There was no placebo group and no healthy-user group, so the study does not establish memory or focus enhancement in healthy people.

key facts

• molecular formula: C17H22N2O4
• molecular weight: 318.37 g/mol
• amino acids: n/a (small molecule, not an amino-acid-chain peptide)
• half-life: 22.05 plus or minus 14.37 minutes in a sparsely reported human conference abstract
• type: synthetic small-molecule cognitive drug; not a peptide
• CAS: 157115-85-0
• 53 patients enrolled in the main active-comparator study
• 41 participants who completed that 56-day study
• 22.05 min reported mean human elimination half-time; low-confidence abstract
• 5.1 to 40.6 mg omberacetam per labeled serving in 10 targeted US products

frequently asked questions

What is Noopept?

Noopept is omberacetam, a synthetic small-molecule cognitive drug built from a proline-glycine scaffold. It is not an amino-acid-chain peptide. The current Russian product is a registered 10 mg oral tablet.

Does Noopept improve memory?

One small active-comparator study reported improvement in patients with vascular or post-traumatic cognitive impairment. It had no placebo group and no healthy-user group, so it does not establish memory enhancement in healthy people.

What is Noopept's human half-life?

A conference abstract reports 22.05 plus or minus 14.37 minutes after a 10 mg oral test dose in patients. Sparse methods and sample reporting make confidence low.

Is Noopept approved?

Russia currently registers Noopept 10 mg tablets under certificate ЛП-N(004920)-(РГ-RU), dated 2024-03-20. Noopept is not FDA-approved. In 2019, FDA warned Peak Nootropics that its Noopept product was an unapproved and misbranded drug and stated that Noopept was not a dietary supplement.

Can a Noopept supplement label be trusted?

Not automatically. A targeted peer-reviewed assay included 10 US products selected because databases listed a piracetam analog. Omberacetam measured 5.1 to 40.6 mg per labeled serving, and some products contained undeclared drug combinations. The sample does not represent every supplement.

related peptides

• bromantane: another Russian CNS drug with an asthenia-focused clinical record
• semax: a Russian peptide drug studied in neurologic populations
• dihexa: a cognitive research chemical with no human trial

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.